Hot Investor Mandate 1: Single Family Office Fund Invests Up to $10M in Early-Stage and $30M in Later-Stage Device & Diagnostics Companies Globally

14 Dec

A single-family evergreen fund headquartered in the US exclusively invests in medical devices; so far there are 15 portfolio companies from the U.S., Europe, and Israel, however the firm is open to investing global companies. The firm has two investment modalities: (1) investing in later-stage, commercial companies with typical check size being around $30M USD and (2) investing in early-stage companies with typical check size being around $10M USD. The earliest the firm will invest in is companies with clinical human data. The firm is active with the companies they invest in and will lead investments. 
 
The firm exclusively invests in medical device companies in a range of diseases states including, but not limited to, oncology, cardiovascular disease, and ophthalmology. The firm also invests in diagnostic devices. The firm is open to all classes of devices. Companies must show at least clinical human data. 
 
The firm will generally seek to take a board seat. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Mandate: VC Firm Invests in US and Japan-Based Companies in All Life Science Sectors, With Strong Interest in Age-Related Diseases

14 Dec

A firm with offices in the US and Japan generally invests in Series A equity rounds, and typically commits a total of $1-4 million over the course of an investment. The firm invests 70% of its capital in the USA and Israel, with the remaining 30% in Japan. Under certain circumstances, the firm will invest outside those regions.  
 
The firm invests in advanced therapeutics, healthcare IT, novel (sensor based IoT) devices and diagnostics, and second generation tools and technologies in the biotech R&D/laboratory innovation field. The firm is open to any indication area, and has a particular interest in diseases that afflict the elderly including Alzheimer’s disease and cancer. DEFTA Partners prefers to invest in technologies at an early stage of development. 
 
The firm is interested in working with high quality management teams. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Mandate: Investment Firm in the UK Invests in Diagnostics & Digital Health Companies Across the Globe, Usually in Pre-Seed to Series A Rounds 

14 Dec

A venture capital firm headquartered in London invests in early-stage global health-tech companies from Pre-Seed to Series A rounds with flexible check sizes. RYSE has partnerships with key accelerators, global pharmaceuticals, and government organizations.  
 
The firm invests in digital health, diagnostics, and data applications such as CRMs and databases. The firm does not invest in therapeutics. The firm is generally indication-agnostic but has a preference in oncology. 
 
The firm will act as a lead and co-investor and typically takes board or observer seats. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Mandate: Early-Stage VC Invests $1-2M in Innovative Life Science Companies, Especially Platform and Cross-Disciplinary Technologies

14 Dec

An early stage VC founded by a group of alumni from a leading university is based in the US. The group currently has $100M, under management. The group focuses on Angel to Series B stage companies across various sectors, including pharmaceutical, medical device, services and tools, and digital health. The typical investment size is between $1M to $2M. The group also syndicates with other investors for larger investments. The firm looks to make investments across the globe. 
 
The firm is currently looking for new opportunities in the life science space. The fund is opportunistic in terms of sectors, subsectors and indications. The fund typically invests in seed rounds and series A rounds. Historically, the fund has been active in life science companies developing innovative platform technologies and cross-disciplinary technologies. 
 
The firm focuses on investments in private companies and typically invests in pre-clinical and early clinical stage companies with strong and experienced management teams. The firm will take a board seat or observer seat occasionally, depending on the investments. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Life Science Nation, Biocat, and Biotechgate Announce RESI Europe Barcelona 2024 – June 17th In-person | 18th & 19th Virtual

7 Dec

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

Life Science Nation (LSN), the visionary force behind the globally acclaimed Redefining Early Stage Investments (RESI) Conference Series, is thrilled to announce a strategic collaboration with Biocat, headquartered in Barcelona, Catalonia, Spain, and Biotechgate, Zurich, Switzerland. Biocat, a catalyzing organization dedicated to transforming the BioRegion of Catalonia into a premier life sciences and health innovation ecosystem in Europe, and Biotechgate, a pioneer in curating and marketing a global business development database tailored for the life science industry, join forces with LSN to bring the RESI global matching platform back to Europe.

The RESI Conference Series has been instrumental in connecting healthcare startups with capital investors, co-development partners, and licensing opportunities worldwide. LSN has a track record of assisting over 400 startups in raising over $5 billion through its investor database, entrepreneurial education, and RESI international partnering events. The LSN partner network, comprising ten categories of investors and licensing partners, actively seeks early-stage innovations in drugs, devices, diagnostics, and digital health for investment portfolio and product pipeline development.

The Power of RESI Partnering

The RESI Partnering platform is a dynamic tool designed to match attendees based on sector, indication, and development phase and is central to the RESI Conference Series. This innovative approach eliminates most ill-fitting meetings, ensuring startups engage with the right investors and licensing partners who align with their specific needs and goals. RESI partnering events run five times annually at life science centers worldwide. They facilitate fundraising CEOs and scientist-entrepreneurs to get out of their local region and into the international market, dramatically increasing the number of potential partners in their pipeline. Fundraising is a numbers game; a startup cannot succeed with one or two conferences yearly. LSN’s startups seek seed funding up to 2M, Series A, 2M-10M, and Series B, 10M-50M. As part of their global partnering campaign initiative, startup companies leverage RESI as a strategic launchpad to meet national and international investors and licensing partners.

“Biocat is unique in Europe because they get it; they understand that shining an international light on their startups and getting them into capital and licensing arrangements early builds the ecosystem’s future,” says Dennis Ford, CEO of Life Science Nation.

Robert Fabregat, CEO of Biocat, said, “LSN has developed a buy-side network that will bring tens of millions of Euros into the BioRegion. Biocat is confident that our rich life science technology ecosystem will capture the attention of global investors and licensing partners and enhance BioRegion’s global footprint.”

Patrik Frei, CEO of Biotechgate, stated, “The Catalan BioRegion, like many others in the European market, is not getting enough of the early-stage investor attention they deserve. Now, startups can attend RESI Europe Barcelona, meet LSN’s global partners, and plug into international RESI events in and outside Europe.”

About RESI Conference Series

RESI is a well-established go-to partnering event series for international scientist-entrepreneurs and fundraising CEOs. It offers a dynamic interactive format featuring one day of face-to-face meetings and two days of global virtual partnering. The RESI Conference Series spans North America, Europe, and Asia, receiving support from governmental agencies, regional international tech hubs, incubators, and accelerators. The 2024 RESI partnering events are scheduled as follows: RESI JPM in San Francisco on January 9th, RESI South Atlanta on March 25th, RESI Europe Barcelona on June 17th, RESI Boston on September 25th, and RESI Asia (location and partner TBD) in November.

About Life Science Nation (LSN)

Life Science Nation (LSN) created the globally recognized Redefining Early Stage Investments (RESI) Conference Series. LSN’s mission is to connect early-stage life science companies with investors and strategic partners, ultimately fostering innovation and driving advancements in the life sciences industry.

About Biocat

Biocat is a strategic stakeholder and catalyst for promoting, transforming and projecting the Catalan life sciences and health innovation ecosystem, known as the BioRegion of Catalonia. It was established in 2006 as a public-private foundation at the behest of the Government of Catalonia and the Barcelona City Council to identify the needs of the BioRegion and implement a strategy and action plan to maximize the economic and social impact of the sector.

About Biotechgate

Biotechgate is a leading business development and licensing database for the entire life science industry, offering a wealth of information on over 69,000 life science company profiles. Thanks to its unique data sourcing process, the profiles include company descriptions, contact information, product pipeline information, financing rounds, and management details, making it an invaluable resource for life sciences start-ups, pharma companies, investors, and other industry professionals. Biotechgate also features 30,000 licensing deals and a clinical trials database containing over 800,000 records from registries around the world.

Check Out the Companies Pitching at RESI JPM 2024

7 Dec

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

With less than 2 months left until LSN’s next conference, RESI JPM 2024, we are very excited to announce the 50+ Innovator’s Pitch Challenge (IPC) finalists who will be pitching to a panel of investors and industry experts and showcasing their posters throughout the day of RESI. All RESI JPM attendees will be able to view their pitches, visit their posters, and “invest” in their favorite companies. After counting these votes, we will announce the Top 3 winners during the cocktail reception at the end of RESI.

We are pleased to work with companies who are sponsored by the following organizations: NIH’s Small Business Education and Entrepreneurial Development (SEED) Office, National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), and Brisbane Economic Development Agency (BEDA).

Please review the companies below, and if you are interested in attending RESI JPM 2024 and learning more about the different registration options we offer, please visit here

RESI JPM 2024 IPC Finalists

RESI-SF-2024-Banner-1100px new

The Right Messaging for Partnering Success 

7 Dec

By Karen Deyo, VP of Product, Israel BD, LSN

Life Science Nation (LSN)‘s flagship RESI conference – RESI JPM, will take place at the Marine’s Memorial Club & Hotel in San Francisco on Tuesday, January 9, 2024, followed by two days of virtual partnering, during JP Morgan Healthcare Week. In preparation for our conference attendees to maximize their partnering efforts we have compiled steps to craft an effective messaging plan to fill your partnering calendar.

Partnering is an involved process with multiple steps that must be taken to ensure optimal results. These steps often require a major time investment, and we forget that even after the hours we’ve poured into the process, none of it matters without a compelling message to pique the interest of a potential partner. Furthermore, this is a process that requires a plan for following up, since, as with any outreach, it will likely take more than one message to the investors to receive a response. These messages should be clear and concise, no more than a paragraph, highlighting your company and what makes it unique.

LSN has developed and consolidated your partnering outreach into four separate messages:

  • Introduction: The first message is the one where you introduce yourself and your company, as well as request a meeting. It’s ok if your target investor does not respond immediately (hence this system). To help them understand your position, it’s important to include the following:
  • Company tagline (5-6 words explaining who you are and what you do)
  • Elevator pitch (1-3 sentences describing the company and tech)
  • Technology differentiation, product innovation, or market position
  • Raise and milestone information
  • Follow-Up 1 (Product/Tech): Why is your product and technology unique? Is it first-in-class? Best-in-class? This is your opportunity to dive into your company’s differentiated value.
  • Follow-Up 2 (Management/Team): Highlight your management and team. How have your people had a notable impact on business development? What makes your people special?
  • Follow-Up 3 (One-Pager): Condense all the important messages you’ve already shared into a one-page tear sheet for quick and easy reference later.

It should go without saying that the perfect message is meaningless without a well-researched and formulated target list and marketing collateral at the ready. Think of the perfect message like how an athlete approaches the arena on game day. It’s the starting shot of a long and exciting process. It won’t replace the training and conditioning that got you to game day, but it’ll ensure you’re off with a competitive edge.

Tuesday, December 19, 12PM ET | Partnering Tutorial – Sign Up

RESI-SF-2024-Banner-1100px new